MetaCap

Cerus (CERS) vs MiMedx Group (MDXG)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Cerus (CERS) has outperformed MiMedx Group (MDXG) over the past year, gaining 14.2% versus a loss of 54.9%. Over five years, MDXG leads with a -58.6% price change compared with -73.5% for CERS. MiMedx Group is the larger company by market cap ($445.1 million vs $373.6 million), about 1.2 times the size.

On valuation, MiMedx Group trades at a lower forward P/E (122.0x vs 123.3x for Cerus). MiMedx Group converts more of its revenue into profit, with a net margin of 11.6% versus -6.7%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CERS+14.20%MDXG-54.88%
+110%+24%-63%
Nov 21, 20251 yearNov 20, 2026
CERS-74.31%MDXG-60.54%
+31%-29%-89%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CERS versus MDXG key metrics
MetricCERSMDXG
Share price$1.85$3.05
Market cap$373.62M$445.07M
1-day change-2.63%-1.93%
YTD return-10.19%-54.95%
1-year return+14.20%-54.88%
5-year return-73.50%-58.62%
Forward P/E123.33122.00
EPS (TTM)$-0.04$-0.13
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$233.80M$418.63M
Revenue growth (YoY)+16.13%+19.99%
Net income (latest FY)$-15.63M$48.58M
Gross margin—82.56%
Operating margin-3.71%15.26%
Net margin-6.68%11.60%
52-week high$3.47$7.45
52-week low$1.59$3.03
Distance from 52-week high-46.69%-59.06%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+177.30%+129.51%
Average volume2.12M1.39M
Shares outstanding201.95M145.93M
Employees261808
SectorHealth CareHealth Care
IndustryMedical/Dental InstrumentsMedical/Dental Instruments

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • CERS has outperformed MDXG by 69.1 percentage points over the past year.
  • MiMedx Group is more profitable, keeping 11.6 cents of every revenue dollar as net income versus -6.7 cents for Cerus.

About Cerus

CERS stock →

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety.

Health Care · Medical/Dental Instruments · 261 employees

About MiMedx Group

MDXG stock →

MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare.

Health Care · Medical/Dental Instruments · 808 employees

CERS vs MDXG FAQ

Which is bigger, Cerus or MiMedx Group?

MiMedx Group (MDXG) is larger, with a market capitalization of $445.07M compared with $373.62M for Cerus (CERS).

Which stock has performed better over the past year, CERS or MDXG?

CERS returned +14.20% over the past 12 months, compared with -54.88% for MDXG (price return, excluding dividends). Past performance does not predict future results.

Are Cerus and MiMedx Group in the same industry?

Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.

More comparisons